Oxford Biomedica (LON:OXB) Issues Earnings Results

Oxford Biomedica (LON:OXB) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.53)) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%.

Oxford Biomedica Trading Down 6.3 %

Shares of OXB opened at GBX 240 ($3.07) on Wednesday. Oxford Biomedica has a 1-year low of GBX 187.83 ($2.40) and a 1-year high of GBX 455 ($5.81). The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The firm’s 50-day moving average price is GBX 329.19 and its 200-day moving average price is GBX 381.47. The firm has a market capitalization of £255.12 million, a price-to-earnings ratio of -1.78 and a beta of 1.09.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.